Michela Gallagher
Baltimore-based AgeneBio received over $3 million in new grant funding as the company looks to make progress with a pair of treatments for conditions related to Alzheimer’s disease.
AgeneBio works on treatments to slow Mild Cognitive Impairment due to Alzheimer’s disease. As part of that work, the funding will be put toward development of a drug that is designed to treat overactivity in the brain, specifically in the hippocampus. The condition causes a noticeable decline in cognitive abilities including memory, according to the Alzheimer’s Association.
One of the Mt. Washington-based company’s therapeutics under development, called GABA-A a5 PAM, is focused on specific receptors that are present in the hippocampus. The company is looking to complete work toward the clinical stage, in which trials involve human patients.
READ FULL ARTICLE HERE
